Corpus Intelligence IC Memo — THE GUIDANCE CENTER INC. 2026-04-26 11:19 UTC
IC Memo — THE GUIDANCE CENTER INC.
Investment Committee Memorandum | AZ | 16 beds | Grade C | EBITDA uplift $1.8M
🛡️ Public data only — no PHI permitted on this instance.
Investment Committee Memorandum

THE GUIDANCE CENTER INC.

CCN 034023 | COCONINO, AZ | 16 beds | April 26, 2026
EBITDA BridgeData Room
C
Investability

1. Target Overview & Investment Thesis

THE GUIDANCE CENTER INC. is a 16-bed safety-net/medicaid heavy in COCONINO, AZ with $24.6M in net patient revenue and a 8.8% operating margin. The hospital serves a payer mix of 10.0% Medicare, 38.9% Medicaid, and 51.0% commercial.

Thesis: Turnaround. Our ML models identify $1.8M in annual EBITDA improvement potential from RCM optimization across 5 levers, lifting margin from 8.8% to 16.1% (+736bps).

Net Revenue HCRIS$24.6M
Current EBITDA COMPUTED$2.2M
Operating Margin COMPUTED8.8%
Occupancy HCRIS74.0%
Revenue / Bed COMPUTED$1.5M
Net-to-Gross HCRIS100.0%
Distress Probability ML57.5%

2. Market Context & Competitive Position

124
AZ Hospitals
-0.8%
State Median Margin
29
Comparable Hospitals

AZ has 124 Medicare-certified hospitals with a median operating margin of -0.8%. The target's margin of 8.8% places it above the state median. Among 29 size-comparable peers (8-32 beds), the median margin is -3.8%. The target performs in line with or above peers.

3. RCM Performance Analysis — Comparable Hospitals

Comps selected by bed count (8-32), prioritizing same-state peers. 29 hospitals in the comp set.

HospitalStateBedsRevenueMargin
THE GUIDANCE CENTER INC. (Target)AZ16$24.6M8.8%
ARIZONA GENERAL HOSPITALAZ16$97.1M10.4%
THE CORE INSTITUTE SPECIALTY HAZ28$91.2M9.2%
MT. GRAHAM REGIONAL MEDICAL CEAZ25$75.2M-2.8%
COBRE VALLEY REG. MEDICAL CENTAZ25$74.9M-10.3%
COPPER QUEEN COMM. HOSP.AZ14$63.5M6.6%
MT. GRAHAM REGIONAL MEDICAL CEAZ25$49.4M-6.8%
BANNER PAYSON MEDICAL CENTERAZ25$49.3M0.0%
AZ SPINE & JOINT HOSPITALAZ23$45.1M19.4%

4. Predicted Improvement Opportunities

Improvement targets set at P75 of comparable peers with 60% gap closure assumption. Coefficients calibrated to published research bands. Total EBITDA uplift: $1.8M (736bps margin improvement).

LeverCurrentTargetEBITDA ImpactMarginRamp
Net Collection Rate93.5%97.0%$517K+210bp18mo
Cost to Collect4.5%2.5%$492K+200bp12mo
Denial Rate Reduction12.0%6.5%$488K+198bp12mo
A/R Days Reduction5200.0%3800.0%$300K+122bp9mo
Clean Claim Rate88.0%96.0%$16K+6bp6mo

5. EBITDA Bridge

Net Collection Rate
$517K
Cost to Collect
$492K
Denial Rate Reduction
$488K
A/R Days Reduction
$300K
Clean Claim Rate
$16K
Total EBITDA Uplift$1.8M
Current EBITDA$2.2M
+ RCM Uplift+$1.8M
Pro Forma EBITDA$4.0M
Current Margin8.8%
Pro Forma Margin16.1%
WC Released (1x)$944K

6. Returns Analysis — Scenario Matrix

5-year hold, 5.5x leverage, 3% organic growth, 10%/yr debt paydown. Base case uses 100% of predicted RCM uplift. Bull case: 130% uplift at lower entry. Bear case: 50% uplift at higher entry.

ScenarioEntryExitEquity InEquity OutMOICIRR
Base Case10.0x10.0x$3.3M$32.3M9.75x57.7%
Base (11x exit)10.0x11.0x$3.3M$36.7M11.05x61.7%
Bull Case9.0x11.0x$3.0M$43.7M14.65x71.1%
Bull (12x exit)9.0x12.0x$3.0M$48.6M16.27x74.7%
Bear Case11.0x10.0x$3.6M$22.2M6.09x43.5%
Bear (11x exit)11.0x11.0x$3.6M$25.6M7.02x47.7%

7. Key Risks & Mitigants

SeverityRisk FactorMitigant
MediumElevated Medicaid exposure (38.9%)Medicaid reimburses below cost in most states. Mitigant: denial reduction lever has highest impact on Medicaid claims
HighElevated distress probabilityModel estimates 57.5% probability of financial distress. Mitigant: distressed entry pricing (7-9x) compensates for risk

8. Data Sources & Methodology Appendix

Data Sources

  • CMS HCRIS Cost Reports (Medicare-certified hospitals)
  • CMS Medicare Utilization (DRG-level volumes)
  • CMS Chronic Conditions (county-level disease prevalence)
  • HCRIS multi-year trend data (financial time series)

Comparable Selection

  • 29 hospitals with 8-32 beds
  • Same-state prioritization (n=31)
  • Comp margins: P25=-10.5% / P50=-3.8% / P75=6.9%

Bridge Methodology

  • Targets: P75 of comparable peers (60% gap closure)
  • Denial: avoidable share = 35% of delta × NPR
  • AR: bad debt coefficient = $0.65 per day per $1K NPR
  • NCR: 60% coefficient on collection rate improvement
  • CDI: 0.75% of Medicare revenue per 0.01 CMI point

Returns Assumptions

  • Leverage: 5.5x entry (84.6% debt / 15.4% equity)
  • Organic growth: 3% annual EBITDA growth
  • Debt paydown: 10% of principal per year
  • Hold period: 5 years

Generated by SeekingChartis on April 26, 2026. All predictions use public data only. Confidence intervals calibrated via split conformal prediction (90% coverage target). This memo is for informational purposes and does not constitute investment advice.